Clinical Trials Logo

Clinical Trial Summary

Observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

Clinical Trial Description

The Study will collect combined clinical and molecular health information for cancer patients in the United States from multiple academic medical centers and community oncology practices. Participants who agree to join the Study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating Institution for submission to Tempus. The specific goal of the Study is to create an outcomes-based dataset for future research to improve cancer treatment. ;

Study Design

Related Conditions & MeSH terms

  • Bile Duct Neoplasms
  • Bladder Cancer
  • Bone Neoplasms
  • Brain Cancer
  • Brain Neoplasms
  • Breast Cancer
  • Cancer of Cervix
  • Cancer of Colon
  • Cancer of Endometrium
  • Cancer of Esophagus
  • Cancer of Gastrointestinal Tract
  • Cancer of Head and Neck
  • Cancer of Kidney
  • Cancer of Larynx
  • Cancer of Liver
  • Cancer of Rectum
  • Cancer of Skin
  • Cancer of Stomach
  • Cancer of the Bile Duct
  • Carcinoma, Renal Cell
  • Colonic Neoplasms
  • Endometrial Neoplasms
  • Esophageal Neoplasms
  • Fallopian Tube Cancer
  • Fallopian Tube Neoplasms
  • Gastrointestinal Neoplasms
  • Head and Neck Neoplasms
  • Kidney Neoplasms
  • Laryngeal Neoplasms
  • Leukemia
  • Liver Neoplasms
  • Lung Cancer
  • Lymphoma
  • Ovarian Cancer
  • Pancreatic Cancer
  • Peritoneal Cancer
  • Prostate Cancer
  • Rectal Neoplasms
  • Skin Neoplasms
  • Spinal Cord Cancer
  • Stomach Neoplasms
  • Uterine Cervical Neoplasms
  • Vulvar Neoplasms

NCT number NCT05179824
Study type Observational
Source Tempus Labs
Contact Gizem Demircioglu
Phone 3474458127
Email [email protected]
Status Recruiting
Start date October 19, 2020
Completion date October 19, 2030

See also
  Status Clinical Trial Phase
Recruiting NCT04574609 - Evaluation of the Impact of the Use of Hypnotherapy Performed by a Virtual Reality Toolalong the Care Pathway of Patients Undergoing Breast Cancer Treatment. N/A
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Active, not recruiting NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Enrolling by invitation NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Active, not recruiting NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT04190381 - A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy N/A
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Suspended NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT02894398 - Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Phase 2